Aarti Pharmalabs Ltd

Aarti Pharmalabs announced that the Board of Directors of the Company at its meeting held on 25 May 2026, inter alia, have recommended the final dividend of Rs 2 per equity Share (i.e. 40%) , subject to the approval of the shareholders.

Net profit of Aarti Pharmalabs declined 30.81% to Rs 61.12 crore in the quarter ended March 2026 as against Rs 88.34 crore during the previous quarter ended March 2025. Sales rose 3.35% to Rs 582.64 crore in the quarter ended March 2026 as against Rs 563.78 crore during the previous quarter ended March 2025. For the full year,net profit declined 35.86% to Rs 174.71 crore in the year ended March 2026 as against Rs 272.40 crore during the previous year ended March 2025. Sales declined 13.98% to Rs 1819.44 crore in the year ended March 2026 as against Rs 2115.07 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales582.64563.78 3 1819.442115.07 -14 OPM %19.4225.83 -20.2921.96 - PBDT109.83137.44 -20 340.05447.59 -24 PBT81.68114.62 -29 235.71360.69 -35 NP61.1288.34 -31 174.71272.40 -36 Powered by Capital Market - Live

Aarti Pharmalabs has revised the meeting of the Board of Directors which was scheduled to be held on 18 May 2026. The meeting will now be held on 25 May 2026.

Aarti Pharmalabs will hold a meeting of the Board of Directors of the Company on 18 May 2026.

The inspection concluded on 27 March 2026, following which the company received a Form 483 with one observation. According to the company, the observation is procedural in nature. The company further stated that it will submit its corrective and preventive action (CAPA) plan along with compliance within the stipulated timeline prescribed by the US FDA. Aarti Pharmalabs (APL) is an established, internationally recognized manufacturer of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, new chemical entities (NCEs), and xanthine derivatives based in India. The company reported a 35.2% decline in consolidated net profit to Rs 47.96 crore, despite a 19.6% decline in revenue from operations to Rs 432.27 crore in Q3 FY26 compared with Q3 FY25. The counter slipped 1.99% to Rs 597 on the BSE. Powered by Capital Market - Live

According to the company, a minor leakage occurred while loading dimethyl sulphate, an industrial chemical, into a tanker. The leak was promptly contained and cleared, and there was no loss of life or damage to property. As a precautionary measure, 22 workers were admitted to a nearby hospital for observation, of whom more than half have already been discharged. The company informed the local police station, following which a First Information Report (FIR) was registered. An investigation into the incident is currently underway, and the company said it is fully cooperating with the authorities. Aarti Pharmalabs added that normal operations at the plant were safely restored within 24 hours of the incident. Aarti Pharmalabs (APL) is an established, internationally recognized manufacturer of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, new chemical entities (NCEs), and xanthine derivatives based in India. The company reported a 35.2% decline in consolidated net profit to Rs 47.96 crore, despite a 19.6% decline in revenue from operations to Rs 432.27 crore in Q3 FY26 compared with Q3 FY25. The counter advanced 2.49% to Rs 631.95 on the BSE. Powered by Capital Market - Live

Aarti Pharmalabs announced that the Board of Directors of the Company at its meeting held on 9 February 2026, inter alia, have recommended the interim dividend of Rs 1.5 per equity Share (i.e. 30%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Net profit of Aarti Pharmalabs declined 35.18% to Rs 47.96 crore in the quarter ended December 2025 as against Rs 73.99 crore during the previous quarter ended December 2024. Sales declined 19.62% to Rs 432.27 crore in the quarter ended December 2025 as against Rs 537.78 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales432.27537.78 -20 OPM %23.6723.91 - PBDT94.28123.66 -24 PBT65.66100.63 -35 NP47.9673.99 -35 Powered by Capital Market - Live

Aarti Pharmalabs will hold a meeting of the Board of Directors of the Company on 9 February 2026.Powered by Capital Market - Live

Revenue from operations fell 8.66% YoY to Rs 418.33 crore in the quarter ended 30 September 2025. Profit before tax (PBT) stood at Rs 38.69 crore in Q2 FY26, down 46.09% from Rs 71.77 crore in the same period last year. Total expenses decreased 2.99% to Rs 379.05 crore in Q2 FY26, compared to Rs 379.05 crore in Q2 FY26. The cost of materials consumed stood at Rs 203.46 crore (down 4.91% YoY), employee benefit expenses were Rs 43.41 crore (up 15.05% YoY) and finance costs stood at Rs 10.67 crore (up 93.64% YoY) during the period under review. On half-year basis, the company's consolidated net profit climbed 29.64% to Rs 77.45 crore on 20.62% decrease in revenue to Rs 804.53 crore in H1 FY26 over H1 FY25. Aarti Pharmalabs (APL) is an established, internationally recognized manufacturer of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, new chemical entities (NCEs), and xanthine derivatives based in India. Powered by Capital Market - Live